证券之星消息，天保基建(000965)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问生物医药平台进展如何了，是否正式运营，如何加入？天保基建回复：您好，公司控股子公司天津天保医药科技发展有限公司自正式运营以来，已取得相关医疗器械经营许可、放射类医疗设备特许经营、以及中药材经营等资质。2025年度天保医药科技公司在医疗器械、中医药业务方面已取得营业收入716万元。未来将继续巩固核心伙伴合作，加深医疗器械、中药材领域业务合作的深度与广度，挖掘新的营收增长点。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.